Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Prostate Cancer

Free Subscription 28.04.2025 1 Acta Radiol 2 BJU Int 2 BMC Cancer 1 Br J Cancer 1 Cancer Imaging 1 Curr Treat Options Oncol 2 Eur Urol 1 Int J Urol 1 J Clin Oncol 2 J Magn Reson Imaging 1 J Nucl Med 1 J Urol 1 PLoS One 2 Prostate

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Acta Radiol

1. LIU X, Yang S, Deng W, Li D, et al
   The diagnostic performance and reader agreement of the Prostate Imaging for Recurrence Reporting system in the evaluation of local recurrence in patients with biochemically recurrent prostate cancer.
   Acta Radiol. 2025 Apr 23:2841851251334364. doi: 10.1177/02841851251334364.
   PubMed         Abstract available
   
   

   
   BJU Int

2. PYRGIDIS N, Chaloupka M, Ebner B, Volz Y, et al
   Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study.
   BJU Int. 2025 Apr 19. doi: 10.1111/bju.16746.
   PubMed         Abstract available
   
   
3. SILAGY AW, Woon DTS, Kostos L, Bernardino R, et al
   Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer.
   BJU Int. 2025 Apr 25. doi: 10.1111/bju.16751.
   PubMed         Abstract available
   
   

   
   BMC Cancer

4. FAN Z, Li D, Yan S, Zhao X, et al
   NEoAdjuvant radiohormonal therapy versus standard of care for oligometastatic prostate cancer (NEAR-TOP): study protocol of a multicenter, open-label, randomised controlled trial.
   BMC Cancer. 2025;25:768.
   PubMed         Abstract available
   
   
5. WANG N, Xu X, Zhong Y, Wan Y, et al
   MBs(NRP2)-based ultrasound molecular imaging for early diagnosis of castration-resistant prostate cancer.
   BMC Cancer. 2025;25:769.
   PubMed         Abstract available
   
   

   
   Br J Cancer

6. LI X, Mamouni K, Zhao R, Bai L, et al
   Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer.
   Br J Cancer. 2025 Apr 19. doi: 10.1038/s41416-025-02993.
   PubMed         Abstract available
   
   

   
   Cancer Imaging

7. MOAVENZADEH SR, Chan DY, Adams ES, Deivasigamani S, et al
   Evaluation of 3D ARFI imaging of prostate cancer: diagnostic reliability and concordance with MpMRI.
   Cancer Imaging. 2025;25:55.
   PubMed         Abstract available
   
   

   
   Curr Treat Options Oncol

8. AYZMAN A, Pachynski RK, Reimers MA
   PSMA-based Therapies and Novel Therapies in Advanced Prostate Cancer: The Now and the Future.
   Curr Treat Options Oncol. 2025 Apr 23. doi: 10.1007/s11864-025-01317.
   PubMed         Abstract available
   
   

   
   Eur Urol

9. GOMEZ RIVAS J, Moreno Sierra J
   Re: Darolutamide in Combination with Androgen-deprivation Therapy in Patients with Metastatic Hormone-sensitive Prostate Cancer from the Phase III ARANOTE Trial.
   Eur Urol. 2025 Apr 23:S0302-2838(25)00208-8. doi: 10.1016/j.eururo.2025.
   PubMed        
   
   
10. GOMEZ RIVAS J, Moreno Sierra J
    Re: [(177)Lu]Lu-PSMA-617 plus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer (ENZA-p): An Open-label, Multicentre, Randomised, Phase 2 Trial.
    Eur Urol. 2025 Apr 22:S0302-2838(25)00207-6. doi: 10.1016/j.eururo.2025.
    PubMed        
    
    

    
    Int J Urol

11. NORO T, Utsumi T, Ishitsuka N, Suzuki Y, et al
    Impact of the COVID-19 Pandemic on Prostate Cancer: Perturbations in Screening and Diagnostic Patterns.
    Int J Urol. 2025 Apr 24. doi: 10.1111/iju.70085.
    PubMed         Abstract available
    
    

    
    J Clin Oncol

12. KUNZ N, Kemper C
    Complementing Anticancer Therapy: Antibody-Drug Conjugates Targeting CD46 as Prostate Cancer Treatment.
    J Clin Oncol. 2025 Apr 22:JCO2500457. doi: 10.1200/JCO-25-00457.
    PubMed        
    
    

    
    J Magn Reson Imaging

13. SAHB FURTADO F
    Editorial for "Prostate Cancer Risk Stratification and Scan Tailoring Using Deep Learning With Abbreviated Prostate MRI".
    J Magn Reson Imaging. 2025 Apr 23. doi: 10.1002/jmri.29806.
    PubMed        
    
    
14. JOHNSON PM, Dutt T, Ginocchio LA, Saimbhi AS, et al
    Prostate Cancer Risk Stratification and Scan Tailoring Using Deep Learning on Abbreviated Prostate MRI.
    J Magn Reson Imaging. 2025 Apr 22. doi: 10.1002/jmri.29798.
    PubMed         Abstract available
    
    

    
    J Nucl Med

15. UNTERRAINER LM, De Leiris N, Unterrainer M, Delker A, et al
    Evidence-Based Clinical Protocols to Monitor Efficacy of [(177)Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data.
    J Nucl Med. 2025 Apr 24:jnumed.124.269431. doi: 10.2967/jnumed.124.269431.
    PubMed         Abstract available
    
    

    
    J Urol

16. MARTIN SC, Gonzalez S, Kwan L, Delfin M, et al
    Evolution of Active Surveillance of Prostate Cancer: Impact of MRI, MRI-guided Biopsy and Focal Therapy.
    J Urol. 2025 Apr 21:101097JU0000000000004559. doi: 10.1097/JU.0000000000004559.
    PubMed         Abstract available
    
    

    
    PLoS One

17. HELLSTERN M, Martinez C, Wallenhorst C, Beyersdorff D, et al
    Correction: Optimal length and temporal resolution of dynamic contrast-enhanced MR imaging for the differentiation between prostate cancer and normal peripheral zone tissue.
    PLoS One. 2025;20:e0322895.
    PubMed         Abstract available
    
    

    
    Prostate

18. SRUTHI KK, Ummanni R
    Valosin-Containing Protein (VCP/p97) Mediates Neuroendocrine Differentiation in Prostate Cancer Cells Through Pim1 Signaling Inducing Autophagy.
    Prostate. 2025 Apr 23. doi: 10.1002/pros.24900.
    PubMed         Abstract available
    
    
19. BACLE C, Mazancourt ES, Abid N, Ruffion A, et al
    Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms.
    Prostate. 2025 Apr 24. doi: 10.1002/pros.24906.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.